Is Oncoplastic Surgery Safe in High-Risk Breast Cancer Phenotypes?

J Surg Oncol

Division of Plastic and Reconstructive Surgery, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA.

Published: September 2024

AI Article Synopsis

  • Oncoplastic surgery (OPS) is a growing method for breast cancer treatment that combines larger partial mastectomy resections with reconstruction techniques, but there's limited evidence on its effectiveness, especially for high-risk types like TNBC and HER2+.
  • A study analyzed data from over 24,000 high-risk breast cancer patients to compare breast cancer-specific survival (BCSS) and surgical complications between OPS with radiotherapy (OPS + RT), partial mastectomy with radiotherapy (PM + RT), and total mastectomy without radiotherapy (MTX-RT).
  • Results showed that OPS + RT had the best 5-year BCSS rates (97.1%), lower complication rates (1

Article Abstract

Background: Oncoplastic surgery (OPS) has increased in popularity over the recent years. It is a form of breast conservation surgery allowing for larger partial mastectomy (PM) resections followed by either volume displacement or volume replacement reconstruction techniques. However, there is a lack of evidence on the effectiveness and safety of OPS with radiotherapy (OPS + RT) in high-risk breast cancer phenotypes, such as triple negative breast cancer (TNBC) and HER2 positive (HER2+) patients. Our aim was to compare the breast cancer-specific survival (BCSS) and postoperative surgical complications in OPS + RT compared to PM alone with radiation (PM + RT) and total mastectomy (MTX) without radiotherapy (MTX-RT).

Methods: Patient data were analyzed from the Surveillance, Epidemiology, and End Results (SEER) cancer registries from January 1, 2012 to December 31, 2020. Patients were stratified according to the type of surgery. Cox regression analysis was performed to assess prognostic factors of BCSS.

Results: A total of 24 621 patients with high-risk breast cancer phenotypes were identified, 180 underwent OPS + RT; 13 402, PM + RT; and 11 039 MTX-RT. OPS + RT was more frequently performed in younger (mean age of 65.53 years, SD: 9.29, p < 0.001), non-Hispanic White (90.5% vs. 77.7% vs. 76.3%) and single women (17.9% vs. 12.1% vs. 13.3%). MTX-RT was usually performed in patients with high histological grade, TNBC, and higher stages. Overall complication rates were higher in the MTX-RT, compared to OPS + RT and PM + RT, 2%, 1.1%, and 0.7%, respectively, p < 0.001. Rates of hematoma and surgical site infections were higher in the MTX-RT group. With a median follow-up of 46 months, OPS + RT had better BCSS rates at 5 years compared to PM + RT and MTX-RT (97.1% vs. 94.7% vs. 89.8%, p < 0.001). MTX-RT was found to be an independent prognostic factor of worse BCSS compared to OPS + RT (hazard ratio [HR] = 2.584; 95% confidence interval [CI]: 1.005-7.171), while PM + RT had no difference compared to OPS + RT (HR = 1.670, 95% CI: 0.624-4.469).

Conclusions: OPS is a safe breast surgical option in patients with HER2+ and TNBC. Patients with high-risk phenotypes who underwent OPS + RT and have similar BCSS and complication rates compared to standard breast surgical options. As such, OPS should be considered as an option whenever breast conservation surgery is being discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.27899DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
high-risk breast
12
oncoplastic surgery
8
cancer phenotypes
8
breast
6
cancer
5
surgery safe
4
safe high-risk
4
cancer phenotypes?
4
phenotypes? background
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!